MedTrace Logo

Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma

NCT05561049 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2022-09-30

No results posted yet for this study

Summary

This is an observational, multi-center, non-interventional study, which is designed to evaluate the safety and efficacy of daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone (D-VTD) Regimens in NDMM patients with renal dysfunction in real-world clinical practice. The data collected in this trial are for subjects with NDMM and renal dysfunction treated with D-VTd regimen and consist of 2 treatment phases, efficacy and safety data from induction phase and consolidation phase.

Conditions

  • Newly Diagnosed Multiple Myeloma

Interventions

DRUG

Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens

Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens

Sponsors & Collaborators

  • The First Affiliated Hospital of Soochow University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-01
Primary Completion
2024-09-30
Completion
2025-09-30
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05561049 on ClinicalTrials.gov